More about Granules India Limited
Fundamentals for Granules India Limited
Regulatory Filings for Granules India Limited
Defence Profits Reach Dharavi's Machinists
From COVID Debt to Green Despair: Industrial Discharge Is Destroying India’s Last Prawn Nurseries
The Hidden Cost of India's Electronics Assembly Push: A 40% E-Waste Surge and the Death of Affordable Repair
The Wedding Loan Trap: How India’s Microfinance Boom Turned Housewives Into Ghost Borrowers and Temple Brass Into EMI Cash
Fundamentals for Granules India Limited
* GRANULES makes the list of companies with the best fundamentals at present.
Business Operations:
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; high potent products; and other products for oncology. Granules India Limited was founded in 1984 and is based in Hyderabad, India.
Revenue projections:
Revenues for GRANULES are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.
Financial Ratios:
| currentRatio | 1.80100 |
|---|---|
| forwardPE | 18.57774 |
| debtToEquity | 29.73500 |
| earningsGrowth | 0.31100 |
| revenueGrowth | 0.24500 |
| grossMargins | 0.65174 |
| operatingMargins | 0.19497 |
| trailingEps | 24.49000 |
| forwardEps | 37.73333 |
GRANULES's current ratio is 1.801, signaling that the company has sufficient cash reserves and current assets to cover its short-term debt obligations. This suggests financial stability, as GRANULES should not face any issues meeting its short-term liabilities with available resources.
Granules India Limited's Forward PE ratio suggests the stock price is reasonable in relation to earnings. It's not overpriced, providing room for future growth, making the stock a potentially valuable investment for those seeking long-term gains.
GRANULES's low Debt-to-Equity ratio demonstrates that the company maintains a healthy balance between equity and debt, avoiding over-leverage. This suggests a low-risk financial profile, giving investors confidence in the company's stability and ability to manage its financial commitments.
With positive earnings and revenue growth, GRANULES is on a path to expand its business. This strong financial performance suggests the company will continue to grow, as increasing profits and revenue highlight a healthy outlook.
GRANULES's forward EPS exceeding its trailing EPS means that the company is expected to increase profitability in the current financial year. This reflects improved earnings potential, signaling that GRANULES is likely to outperform its previous year's financial performance.
Price projections:
Over time, price projections for GRANULES have risen steadily, pointing to growing optimism among analysts about the company's future. This upward trend suggests a positive outlook for GRANULES's continued growth.
Recommendation changes over time:
The recent buy bias from analysts suggests GRANULES is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, GRANULES appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
From Lifesaving Drugs to Sick Units: The Hidden Energy Crisis Inside India’s Pharma Clusters
From Price Pressures to Profit Power: The MSME Playbook Redefining India’s Economy
₹90 Crore Bet Signals a Massive Shift in India’s Rural Economy